Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ARQT Arcutis Biotherapeutics
16.390-0.340-2.03%
Close
02/08 16:00 ET
High
16.800
Open
16.740
Turnover
11.90M
Low
16.310
Pre Close
16.730
Volume
721.96K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Arcutis Biotherapeutics (ARQT) and Genenta Science SpA Sponsored ADR (GNTA)
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in MarchWESTLAK
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, MarketBeat reports. Six equities
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Mizuho Securities Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics (ARQT) Receives a Buy From Mizuho Securities
Analysts Offer Insights on Healthcare Companies: Concert Pharma (CNCE) and Arcutis Biotherapeutics (ARQT)
Arcutis up 9% as Cowen Says to Add to Positions as Shares Are 'Meaningfully Discounted'
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 3.5%
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating)'s share price shot up 3.5% on Thursday . The stock traded as high as $14.67 and last traded at $14.67. 8,711 shares traded hands during mid-da
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast cream (0.3%) in adults with chronic plaque
Company Overview
More
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
CEO： Mr. Todd Franklin Watanabe
Market： NASDAQ
Listing Date： 01/31/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet